期刊
JOURNAL OF CHEMOTHERAPY
卷 28, 期 3, 页码 218-224出版社
TAYLOR & FRANCIS LTD
DOI: 10.1179/1973947815Y.0000000045
关键词
Bevacizumab; Brain metastasis; NSCLC
资金
- Municipal Commission of Sicience and Technology [2131107002213040]
This retrospective analysis evaluated the mechanism of bevacizumab plus chemotherapy (BV+CT) for preventing brain metastasis derived from lung cancer. From the total of 159 patients with advanced non-small cell lung cancer (NSCLC), 110 received BV+CT and 49 received CT. After medication, both groups had 15 patients with brain metastases (14 vs 31%, P<0.05). With BV+CT treatment, 40 patients (33.89%) survived, whereas only 11 patients (18.64%) survived with CT treatment. The outcome for the BV+CT group was significantly better than that for the CT group only for vascular endothelial growth factor (VEGF)-positive patients. A post-treatment with BV+CT was significantly reduced than with CT only for patients with high carbonic anhydrase-9 (CA9) expression. This retrospective analysis provides supportive evidence that BVzCT can significantly reduce the incidence of brain metastasis in patients with advanced NSCLC compared with CT alone. Vascular endothelial growth factor - positive patients may benefit more from BV treatment and the outcomes with BV may be related to CA9 expression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据